CENTOGENE AG CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

Transparency directive : regulatory news

13/06/2019 14:00

DGAP-News: CENTOGENE AG / Key word(s): Study
CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

13.06.2019 / 14:00
The issuer is solely responsible for the content of this announcement.


CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia

Cambridge, MA USA & Rostock, GERMANY, 13 June 2019 - CENTOGENE today announced a new research study to identify genetic variants in patients with hypophosphatasia (HPP). The one year multicentric research study will be conducted in Rostock, Germany and Bogotá, Colombia.

"We are excited to be leveraging our genetic expertise and knowledge to further identify and better understand the genetic mutations that play a role in the clinical spectrum of HPP," said Dr. Arndt Rolfs, CEO CENTOGENE. "We are deeply committed to bringing hope to patients and their families by shortening the diagnostic odyssey, and we are proud to be working on this important study to better understand mutations in the ALPL gene. We are focused on leveraging the insights gained from this research to help to accelerate the diagnosis of our patients."

HPP is an inherited rare metabolic disease that is characterized by low tissue-nonspecific activity of the enzyme alkaline phosphatase (ALP), which plays an essential role in bone and teeth building and maintenance. Known pathogenic variants in the ALPL gene lead to HPP, however, an unknown percentage of clinically diagnosed HPP patients do not carry ALPL pathogenic variants. The research is designed to identify mutations in genes that may cause a phenocopy of HPP and therefore being mixed up or not diagnosed.

About CENTOGENE

CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity and our innovative biomarkers.

As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for our patients with rare diseases and their families.

 

###


CENTOGENE AG
Ross Bethell
Director, Corporate Communications
ross.bethell@centogene.com



13.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


824083  13.06.2019 

fncls.ssp?fn=show_t_gif&application_id=824083&application_name=news&site_id=symex


Other stories

20/06/2019 10:49
20/06/2019 08:36
20/06/2019 02:05
20/06/2019 01:01
20/06/2019 02:32
20/06/2019 00:30
20/06/2019 07:46
19/06/2019 12:14
19/06/2019 14:08
20/06/2019 11:22
20/06/2019 09:32
20/06/2019 02:05
19/06/2019 19:31
19/06/2019 14:09
20/06/2019 05:15
19/06/2019 18:00
20/06/2019 01:01
19/06/2019 22:30
20/06/2019 08:30
20/06/2019 01:01
20/06/2019 06:57
19/06/2019 15:53
19/06/2019 19:11
20/06/2019 10:26
19/06/2019 22:45
20/06/2019 11:15
20/06/2019 08:15
19/06/2019 23:46
19/06/2019 22:45
20/06/2019 08:52
20/06/2019 10:23
20/06/2019 09:24
19/06/2019 13:29
20/06/2019 08:46
19/06/2019 21:33
20/06/2019 01:01
18/06/2019 18:42
19/06/2019 11:55
20/06/2019 01:01
20/06/2019 01:01
20/06/2019 01:01
19/06/2019 12:41